Company

Key dates

EryPharm, a spin-off from Sorbonne University, is the entrepreneurial extension of academic research carried out by Prof. Luc Douay’s team which pioneered all stages of fundamental research (see publications):

2002

Start of the concept of cultured red blood cells (cRBCs) in vivo in animals

2005

Production of cRBCs in vitro from Human Hematopoietic Stem Cells (HSC)

2011

First human injection of cRBCs: demonstration of the concept validity and greater transfusion efficacy of cRBCs compared to native RBCs

2015

Establishment of the basic principles of mass production technology

2016

Creation of EryPharm

2020

Lifting of the last technical barriers to initiate upscaling Investment in a new pharmaceutical production site

2022

Trial to confirm the non-toxicity of the product

2023

Trial to confirm the benefits of cRBCs

Continuation of clinical trials

Industrialization

2030

Go to market authorization